Vectoring into functional genomics

OXFORD - Braced with its just completed Eur24.4 million ($26.3 million) funding round, IntroGene B.V. plans to use a piece of its new cash to project its core gene therapy technology into the functional genomics arena.

IntroGene (Leiden, the Netherlands) is teaming up with Tibotec N.V. (Mechelen, Belgium), a drug discovery company focused on infectious diseases, to establish a 50-50 functional genomics joint venture, Galapagos Genomics NV. IntroGene CEO Dinko Valerio sees this approach as being the best way to leverage more value from the company's core adenoviral vector technology...